Громыко Г. А., Казаков А. И., Четвериков С. Ю., Диденко М. В., Пасенов Г. С., Яшин С. М. ИСПОЛЬЗОВАНИЕ АНАЛИЗА QRS ДЛЯ ОПРЕДЕЛЕНИЯ РИСКА ЖЕЛУДОЧКОВЫХ АРИТМИЙ У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И ИМПЛАНТИРОВАННЫМИ КАРДИОВЕРТЕРАМИ-ДЕФИБРИЛЛЯТОРАМИ. Вестник аритмологии. 2013;(72):14-17.
1. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.// Circullation 2006; 114; 1088-1132.
2. Bayés de Luna A, Coumel P, Leclercq JF Ambulatory sudden cardiac death; mechanisms of production of fatal arrhythmia on the basis of data from 157 cases.// Am Heart J. 1989 Jan;117(1); 151-9.
3. Mjerberg RJ. Heart Disease, A Textbook of Cardiovascular medicine.// 6th ed. p 895.
4. van Welsenes GH, Borleffs CJ, van Rees JB et. al. Improvements in 25 Years of Implantable Cardioverter Defibrillator Therapy.// Neth Heart J. 2011 Jan;19(1); 24-30. Epub 2010 Dec 22.
5. The Antiarrhythmics versus Implantable Defibrillators(AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal in ventricular arrhythmias.// N Engl J Med. 1997;337; 1576 -1583
6. Kuck KH, Cappato R; Siebels J et al. Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest The Cardiac Arrest Study Hamburg (CASH). //Circulation 2000;102;748-754.
7. Connolly SJ; Gent M; R. S. Roberts; Canadian Implantable Defibrillator Study (CIDS) A Randomized Trial of the Implantable Cardioverter Defibrillator Against Amiodarone. // Circulation 2000;101;1297-1302.
8. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.// N Engl J Med 2002;346; 877- 83.
9. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure.// N Engl J Med 2005;352; 225-237
10. http; //www.escardio.org/communities/EHRA/publications /Documents/ehra-white-book-2011.pdf
11. Hammill SC, Kremers MS, Stevenson LW et al. Review of the Registry’s Fourth Year, Incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure // Heart Rhythm. 2010 Sep;7(9); 1340-5.
12. Parkash R, Sapp JL, Basta M et al. Use of Primary Prevention ImplantableCardioverter-Defibrillators in a population-Based Cohort Is Associated With a Significant Survival Benefit// Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4); 706-13.
13. Leenhardt A, Defaye P, Mouton E et al. First inappropriate implantable cardioverter defibrillator therapy is often due to inaccurate device programming; analysis of the French OPERA registry// Europace (2012)14, 1465-1474.
14. Selvester RH,Wagner JO, Runin HB. Quantitation of myocardial infarct size and location by electrocardiogram and vectorcardiogram. //In; Snellen HA, Hekmer HC, Hugenholtz PG, Van Bemmel JH, editors. Quantitation in cardiology. Baltimore; The Williams and Wilkins Company; 1972. p. 31.
15. Strauss DG, Selvester RH, Lima JA et al. ECG Quantification of Myocardial Scar in Cardiomyopathy Patients With or Without Conduction Defects; Correlation With Cardiac Magnetic Resonance and Arrhythmogenesis// Circ Arrhythm Electrophysiol; 2008;1;327-336.
16. Wilkoff BL, Auricchio A, Brugada J et al. HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs); Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations// Europace (2008)10, 707-725.
17. Schron EB, Exner DV Yao Q et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial; impact of therapy and influence of adverse symptoms and defibrillator shocks.// Circulation. 2002 Feb 5;105(5); 589-94.
18. Poole JE, Johnson GW, Hellkamp AS et al. Prognostic importance of defibrillator shocks in patients with heart failure. // N Engl J Med. 2008 Sep 4;359(10); 1009-17.
19. Buxton AE, Lee KL, Hafley GE et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease; lessons from the MUSTT study.// J Am Coll Cardiol. 2007 Sep 18;50(12); 1150-7. Epub 2007 Sep 4.
20. Goldenberg I, Vyas AK, Hall WJ et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.// J Am Coll Cardiol. 2008 Jan 22;51(3); 288-96.
21. Kramer DB, Friedman PA, Kallinen LM et al. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators // Heart Rhythm. 2012 Jan;9(1); 42-6. Epub 2011 Sep 3.
22. Scott PA, Morgan JM, Carroll N et al. The Extent of Left Ventricular Scar Quantified by Late Gadolinium Enhancement MRI Is Associated With Spontaneous Ventricular Arrhythmias in Patients With Coronary Artery Disease and Implantable Cardioverter-Defibrillators.// Circ Arrhythm Electrophysiol. 2011;4; 3 324-330.
23. Goetti R, Feuchtner G, Stolzmann P et al. Delayed enhancement imaging of myocardial viability; low-dose high-pitch CT versus MRI.// Eur Radiol. 2011 Oct;21(10); 2091-9. Epub 2011 May 15.
24. Gerstenblith G., Marban E., Weiss RG et al. ECG Quantification of Myocardial Scar in Cardiomyopathy Patients With or Without Conduction Defects ; Correlation With Cardiac Magnetic Resonance and Arrhythmogenesis.// Circ Arrhythm Electrophysiol 2008; 1; 327-336.
25. Strauss DG, Poole JE, Wagner GS et al. An ECG index of myocardial scar enhances prediction of defibrillator shocks; An analysis of the Sudden Cardiac Death in Heart Failure Trial.// Heart Rhytm 2011; 8(1); 38-45.
